Canada - English - Health Canada

mint pharmaceuticals inc - entacapone - tablet - 200mg - entacapone 200mg

Canada - English - Health Canada

mylan pharmaceuticals ulc - entacapone - tablet - 200mg - entacapone 200mg - catechol-o-methyltransferase (comt) inhibitors

European Union - English - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - entacapone - film-coated tablet - entacapone 200 mg - anti-parkinson drugs

United States - English - NLM (National Library of Medicine)

avpak - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

american health packaging - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies ). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone tablets' effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone tablets' effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies ). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets’ effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end‑of‑dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.